Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

Lamichhane, N., Melas, N., Bergqvist, V., Ekholm, N.-P., Olén, O., Ludvigsson, J. F., Hjortswang, H., Marsal, J., Eriksson, C., & Halfvarson, J. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 69(6), 2175–2183. https://doi.org/10.1007/s10620-024-08422-9

Authors:

N Lamichhane

N Melas

V Bergqvist

N-P Ekholm

O Olén

J F Ludvigsson

H Hjortswang

J Marsal

C Eriksson

J Halfvarson

Affiliated Authors: